BaroPharm Valuation Multiples

BaroPharm is valued at $60M as of November 2026. In the last fiscal year, BaroPharm revenue was $130M.

BaroPharm Overview

About BaroPharm

BaroPharm Co operates a healthcare platform business based on IT technology that supports the efficiency of pharmaceutical ordering and management operations in pharmacies. Its key services consist of integrated pharmaceutical ordering, price and inventory comparison, payment and return notifications, and out-of-stock and restock alerts, along with functions such as pharmaceutical information search, education, community features, and management support.


Founded

2009

HQ

South Korea

Employees

N/A

Financials (Last FY)

Revenue: $130M
Net Income: $5M

Market Cap

$60M

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

BaroPharm Financials

BaroPharm reported last fiscal year revenue of $130M.

In the same fiscal year, BaroPharm generated $24M in gross profit and $5M in net income.


BaroPharm P&L

In the most recent fiscal year, BaroPharm reported revenue of $130M and net income of $5M.

BaroPharm is profitable as of last fiscal year, with gross margin of 19% and net margin of 4%.

See analyst estimates for BaroPharm
Last FY202620272028
Revenue$130M
Gross Profit$24M
Gross Margin19%
EBIT Margin4%
Net Profit$5M
Net Margin4%

Financial data powered by Morningstar, Inc.

BaroPharm Stock Performance

BaroPharm has current market cap of $60M.


BaroPharm's stock price is $5.01.

BaroPharm has an EPS (earnings per share) of $0.44.

See more trading valuation data for BaroPharm
Market CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$60M-8.4%---$0.44

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

BaroPharm Valuation Multiples

BaroPharm Financial Valuation Multiples

As of November 18, 2026, BaroPharm has market cap of $60M.

BaroPharm has a P/E ratio of 11.4x.

Last FY202620272028
P/E11.4x

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified BaroPharm Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

BaroPharm Margins & Growth Rates

BaroPharm grew revenue by 30% and net profit by 105% in the last fiscal year.

In the most recent fiscal year, BaroPharm reported gross margin of 19% and net margin of 4%.

See estimated margins and future growth rates for BaroPharm

BaroPharm Margins

Last FY2026202720282029
Gross Margin19%19%
EBIT Margin4%4%
Net Margin4%4%

BaroPharm Growth Rates

FY+1/FY26/2727/2828/29
Revenue Growth30%
Gross Profit Growth53%
EBIT Growth156%
Net Profit Growth105%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

BaroPharm Competitors

BaroPharm competitors include Vulcan Two Group, Cango, Gear4music, Kamux, CarParts.com, Carma, MARX Biotech, Online Brands Nordic, Marks Electrical Group and Aromatica Co.

Most BaroPharm public comparables operate across Pharmacies, Consumer E-commerce and Vertical E-commerce.

Last FYEV/RevenueEV/EBITDA
RevenueEBITDALast FYLTM2027ELast FYLTM2027E
Vulcan Two Group-($2M)-1.1x(31.9x)28.4x
Cango$688M($317M)0.1x0.3x(0.3x)(0.9x)
Gear4music$252M$24M0.3x0.3x3.0x4.0x
Kamux$964M$16M0.1x0.1x6.2x12.6x
CarParts.com$548M($28M)0.1x0.2x(2.8x)131.6x
Carma$77M($22M)0.7x0.5x(2.3x)(2.8x)
MARX Biotech$19M$3M3.6x-25.3x-
Online Brands Nordic$47M$2M1.2x0.9x30.2x11.4x

This data is available for Pro users. Sign up to see all BaroPharm competitors and their valuation data.

Start Free Trial

BaroPharm VC Funding History

Before going public, BaroPharm raised $25M in total equity funding, across 2 rounds.


BaroPharm Funding Rounds

DateStageInvestorsRaisedValuationRev. MultipleDeal Summary
Nov-24Series AMirae Asset Venture Investment; Company K Partners; CJ Logistics$14M-Baropharm is a Korean pharmacy management platform specializing in digital transformation within the pharmacy sector. The company operates a two-way platform connecting pharmacies with pharmaceutical companies and wholesalers, offering solutions that streamline operations and boost efficiency. In November 2024, Baropharm completed a pre-IPO funding round raising $13.5 million (19 billion KRW) from investors including Mirae Asset Securities and CJ Korea Express, bringing cumulative funding to $28.6 million. The company reported having over 20,000 pharmacies actively using its platform nationwide as it prepared for its IPO. Baropharm planned to use the new capital to develop its subsidiary BRP Labs' health-focused initiatives and invest in pharmacy sales activation projects.
Aug-24Series AKDB Capital; SBVA; Mirae Asset Venture Investment; Company K Partners; Mirae Asset Capital$11M-BaroPharm is a South Korea-based total pharmacy management platform founded in 2021 by CEO Seulgi Kim and COO Kyungdo Shin. The platform serves over 20,000 pharmacies nationwide, covering 80% of the market, with cumulative orders exceeding ₩3 trillion. It offers integrated drug ordering, restock alerts, return management, and a pharmacy-focused community. On August 29, 2024, BaroPharm secured ₩15 billion (approximately $11.2 million USD) in pre-IPO funding led by SBVA, with participation from KDB Capital, Mirae Asset Capital, Mirae Asset Venture Investment, and Company K Partners. This round brought the company's total investment to ₩35 billion (about $26.1 million USD). BaroPharm appointed Mirae Asset Securities as its IPO lead manager in March 2024 and is advancing with the IPO process. The funding supports acceleration of growth, expansion into healthcare commerce and B2B services leveraging data, and strengthening the platform's ecosystem for the pharmaceutical industry.

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About BaroPharm

When was BaroPharm founded?BaroPharm was founded in 2009.
Where is BaroPharm headquartered?BaroPharm is headquartered in South Korea.
Is BaroPharm publicly listed?Yes, BaroPharm is a public company listed on Korea Exchange.
What is the stock symbol of BaroPharm?BaroPharm trades under 0153R0 ticker.
When did BaroPharm go public?BaroPharm went public in 2026.
Who are competitors of BaroPharm?BaroPharm main competitors include Vulcan Two Group, Cango, Gear4music, Kamux, CarParts.com, Carma, MARX Biotech, Online Brands Nordic, Marks Electrical Group, Aromatica Co.
What is the current market cap of BaroPharm?BaroPharm's current market cap is $60M.
What is the current revenue of BaroPharm?BaroPharm's last fiscal year revenue is $130M.
What is the current revenue growth of BaroPharm?BaroPharm revenue growth (vs. last FY) is 30%.
Is BaroPharm profitable?No, BaroPharm is not profitable.
How many companies BaroPharm has acquired to date?BaroPharm hasn't acquired any companies yet (or none have been disclosed publicly).
In how many companies BaroPharm has invested to date?BaroPharm hasn't invested in any companies yet (or none have been disclosed publicly).

See public comps similar to BaroPharm

Lists including BaroPharm

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial